A Preliminary Study in Search of Potential Peptide Candidates for a Combinational Therapy with Cancer Chemotherapy Drug
- 80 Downloads
Cancer which caused by the growth and spreading of abnormal cells in an uncontrolled manner remains a major cause of death affecting millions of people. The current cancer chemotherapy treatment modalities have several disadvantages, mostly related to their undesirable side effects. In this study, we explore the potencies of selected cell penetrating antimicrobial peptides in combination with the widely used chemotherapy drug, Doxorubicin (DOX), to increase the specificity of anticancer chemotherapy. Screening the potential peptide candidates to be developed into chemotherapy drug combination led to identification of two most potent peptides, Tachyplesin 1 (TCH) and Latarcin 1 (LTC). Cell viability of normal liver cells was reduced to 50% by 20 µM of TCH or LTC, while liver cancer cell lines lost 50% of their viability at approximately 4 µM of these peptides. The combination of DOX with TCH peptide showed the higher levels of lactate dehydrogenase (LDH) leakage from cancer cells (80%) compared to normal cells (30%). The combinational treatment DOX-peptide showed significant (P < 0.01) increase in caspase 3/7 activity compared to DOX alone. Pre-treatment of the cells with TCH peptides prior to DOX treatment considerably increased the Caspase 3/7 activities in both cell types with significant increase (P < 0.05) in cancer cells compared to normal cells. Our study demonstrate that TCH peptide is a potential anticancer peptide that could be used in combinational therapy with cancer chemotherapy drugs.
KeywordsTachyplesin 1 Latarcin 1 Doxorubicin Anticancer chemotherapy Drug delivery
This project was funded by the Ministry of Higher Education Malaysia (ERGS grant ER016-2013A) and Postgraduate Fund of University of Malaya (PG081-2014A).
Compliance with Ethical Standards
Conflict of interest
The authors have declared that they have no conflict of interests.
Research Involving Human and Animal Rights
This article does not contain any studies with human participants or animals performed by any of the authors.
- Allred LE, Porter KR (1979) Morphology of normal and transformed cells. In: Hynes R (ed) Surfaces of normal and malignant cells. Wiley, New York, pp 21–61Google Scholar
- Domagala W, Koss LG (1980) Surface configuration of human tumor cells obtained by fine needle aspiration biopsy. Scan Electron Microsc 1:101–108Google Scholar
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2012) Cancer incidence and mortality worldwide: IARC cancer base. International agency for research on cancer. GLOBOCAN 1.0(11)Google Scholar
- Furlong SJ, Mader JS, Hoskin DW (2006) Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen. Oncol Rep 15:1385–1390Google Scholar
- Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB (2000) In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 15:151–160Google Scholar
- Nakamura T, Furunaka H, Miyata T, Tokunaga F, Muta T, Iwanaga S, Niwa M, Takao T, Shimonishi Y (1988) Tachyplesin, a class of anti-microbial peptide from the hemocytes of the horseshoe crab (Tachypleus tridentatus). Isolation and chemical structure. J Biol Chem 263:16709–16713Google Scholar
- Rothan HA, Ambikabothy J, Abdulrahman AY, Bahrani H, Golpich M, Amini E et al. (2015) Scalable production of recombinant membrane active peptides and its potential as a complementary adjunct to conventional chemotherapeutics. PLoS ONE 10(9):e0139248. https://doi.org/10.1371/journal.pone.0139248
- Smolarczyk R, Cichon T, Szala S (2009) Peptides: a new class of anticancer drugs. Postepy Hig Med Dosw 63:360–368Google Scholar
- Utsugi T, Schroit AI, Connor J, Bucana CD, Fidler IJ (1991) Elevated expression of phosphatidylserine in the outer leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 51:3062–3066Google Scholar